DNLI vs LLY vs ABBV vs BIIB

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 21. 7x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Denali Therapeutics Inc. (DNLI) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Biogen Inc.

(BIIB) is the cheapest at 21. 7x versus AbbVie Inc. at 85. 5x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to -63. 7% for Denali Therapeutics Inc. (DNLI). Over 10 years, the gap is even starker: LLY returned +1238% versus BIIB's -29. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Denali Therapeutics Inc. 's 1. 82β — meaning DNLI is approximately 438% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Denali Therapeutics Inc. (DNLI) carries a lower debt/equity ratio of 3% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 0. 0% for Denali Therapeutics Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for DNLI. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 0x forward P/E versus 28. 2x for Eli Lilly and Company — 15. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DNLI: 75. 0% to $34. 50.

In this comparison, ABBV (3.

2% yield), LLY (0. 6% yield) pay a dividend. DNLI, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Denali Therapeutics Inc. (DNLI) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1238%, DNLI: -8. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DNLI is a small-cap quality compounder stock; LLY is a large-cap high-growth stock; ABBV is a large-cap income-oriented stock; BIIB is a mid-cap quality compounder stock. LLY, ABBV pay a dividend while DNLI, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.